257 patents currently held
239 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2031. from the record
Of the 239 now held by other companies, 61 name President and Fellows of Harvard College as their current owner, and 178 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2031
Next term end
202
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2033 · Low confidence
Also notable
Ends Oct 2033 · High confidence
Also notable
Ends Oct 2033 · Low confidence
Also notable
Ends Oct 2033 · Low confidence
Also notable
Ends Mar 2040 · Low confidence
Also notable
Ends Dec 2033 · Medium confidence
Also notable
Ends Oct 2033 · Medium confidence
Also notable
Ends Dec 2035 · Low confidence
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US 11,041,173
Cited by 238 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
CRISPR-Cas Component Systems, Methods and Compositions for Sequence Manipulation
US 8,795,965
Cited by 808 later US patents, top 1% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
CRISPR-Cas Systems and Methods for Altering Expression of Gene Products
US 8,945,839
Cited by 668 later US patents, top 1% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
CRISPR-Cas Component Systems, Methods and Compositions for Sequence Manipulation
US 9,840,713
Cited by 367 later US patents, top 1% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Methods and Compositions for Prime Editing Nucleotide Sequences
US 11,643,652
Cited by 57 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Functional Genomics Using CRISPR-Cas Systems, Compositions, Methods, Screens and Applications Thereof
US 10,781,444
Cited by 193 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2033.
CRISPR-Cas Nickase Systems, Methods and Compositions for Sequence Manipulation in Eukaryotes
US 8,889,356
Cited by 664 later US patents, top 1% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Novel CRISPR Enzymes and Systems
US 10,648,020
Cited by 35 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Dec 2033 · Medium confidence
Cited by 322 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2033.
now held by President and Fellows of Harvard College
Also notable
Ends Dec 2035 · Low confidence
Cited by 77 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
now held by President and Fellows of Harvard College
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Compounds for the Treatment of Tuberculosis (US 10,301,294) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 2 fees due Dec 25 to 27, 2026 · next Dec 25
- 2 fees due Jan 18 to 30, 2027 · next Jan 18
- 4 fees due Feb 6 to 20, 2027 · next Feb 6
- 1 fee due Mar 26, 2027The maintenance fee for Multiplexed Genetic Reporter Assays and Compositions (US 11,767,534) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 3 fees due Apr 24, 2027
- 3 fees due May 7 to 26, 2027 · next May 7
- 3 fees due Jun 3 to 26, 2027 · next Jun 3
- 5 fees due Aug 13 to 27, 2027 · next Aug 13
- 1 fee due Sep 5, 2027The maintenance fee for Engineered Muscle Targeting Compositions (US 11,920,150) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 3 fees due Oct 14 to 28, 2027 · next Oct 14
- 5 fees due Nov 12 to 19, 2027 · next Nov 12
Recent changes
- Nov 10Assignment recorded on 1 record: Choudhury, Sourav to The Broad Institute, Inc. Recorded Nov 10, 2026, executed May 23, 2019. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76705, frame 254.
- Nov 10Assignment recorded on 1 record: Heidenreich, Matthias to The Broad Institute, Inc. Recorded Nov 10, 2026, executed Aug 12, 2020. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76705, frame 443.
- 21 of the patents on this record were granted since Aug 23, 2026
- 2 terms have ended since Aug 23, 2026
- Sep 4 US 10,064,853 Compounds for Use in Methods for Treating Diseases or Conditions Mediated by Protein Disulfide Isomerase · lapsed on the fee record
- Aug 30 US 11,427,869 T Cell Balance Gene Expression, Compositions of Matters and Methods of Use Thereof · lapsed on the fee record
What they patent
The largest of its 202 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,629,865 | Modified Saponins For the Treatment of Fungal Infections In force · High confidence | In force | High confidence | |
| US 10,619,195 | Gene-Expression Profiling with Reduced Numbers of Transcript Measurements In force · Medium confidence | In force | Medium confidence | |
| US 8,987,217 | Modified Saponins for the Treatment of Fungal Infections In force · High confidence | In force | High confidence | |
| US 9,422,262 | Compounds and Methods for Treating Diseases Mediated by Protease Activated Receptors In force · High confidence | In force | High confidence | |
| US 11,767,534 | Multiplexed Genetic Reporter Assays and Compositions In force · High confidence | In force | High confidence | |
| US 12,522,872 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy In force · High confidence | In force | High confidence | |
| US 9,682,064 | Compounds for the Treatment of Mycobacterial Infections held by Massachusetts General Hospital In force · High confidence | In force | High confidence | |
| US 10,766,872 | Compounds for the Treatment of Mycobacterial Infections In force · High confidence | In force | High confidence | |
| US RE48,105 | Compounds for the Treatment of Mycobacterial Infections In force · Low confidence | In force | Low confidence | |
| US 9,657,329 | Propeptide-Luciferase Fusion Proteins and Methods of Use Thereof held by The Broad Institute Inc., The General Hospital Corporation and Instituto Carlos Slim de la Salud, A.C. In force · High confidence | In force | High confidence |
Also on record, not counted in the 257: 239 patents in force now held by others · 28 patents ended · 449 applications pending · 230 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.